Home > Gastroenterology > MR-Linac-delivered adaptive radiation therapy promising in pancreatic cancer

MR-Linac-delivered adaptive radiation therapy promising in pancreatic cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Practical Radiation Oncology
Reuters Health - 09/10/2020 - Stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) delivered on an MR-Linac provided "encouraging" early local pancreatic cancer control with minimal severe treatment-related toxicity in a single-center retrospective analysis. "Our MR-Linac was the second clinically operational unit in the U.S. starting in April 2018," Dr. Michael Chuong of the Miami Cancer Institute told Reuters Health by email. "Our treatment regimen...delivers a very high ablative dose in only five days instead of the more common five to six weeks." While the team's initial outcomes, reported in the current analysis, are "very encouraging," he said, "there needs to be longer follow up. We are analyzing outcomes now that have a longer follow up in a larger population of patients." "Historically, two-year overall survival is <20% with standard chemotherapy and radiation therapy, although with the use of high ablative radiation dose this...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on